Stereotactic Body Radiation Therapy for Oligoprogressive Disease in Androgen-Suppressed Prostate Cancer: Primary Endpoint Analysis of the TRAP Trial.

Saved in:
Bibliographic Details
Title: Stereotactic Body Radiation Therapy for Oligoprogressive Disease in Androgen-Suppressed Prostate Cancer: Primary Endpoint Analysis of the TRAP Trial.
Authors: Patel P; The Royal Marsden NHS Foundation Trust, London, United Kingdom. Electronic address: priyankahpatel@doctors.org.uk., Dreibe S; The Royal Marsden NHS Foundation Trust, London, United Kingdom., Attard G; University College London Cancer Institute, London, United Kingdom; University College London Hospital, London, United Kingdom., Cole A; Queen's University Belfast, Lisburn Road Belfast, United Kingdom., Diez P; Radiotherapy Physics, National Radiotherapy Trials Quality Assurance Group (RTTQA), Mount Vernon Cancer Centre, Northwood, United Kingdom., Frew J; Newcastle upon Tyne Hospital NHS Foundation Trust, Newcastle-Upon-Tyne, United Kingdom., Guevara J; The Royal Marsden NHS Foundation Trust, London, United Kingdom., Levine D; The Royal Marsden NHS Foundation Trust, London, United Kingdom., McDonald F; The Royal Marsden NHS Foundation Trust, London, United Kingdom; The Institute of Cancer Research, London, United Kingdom., Mullassery V; Guys and St Thomas's NHS Foundation Trust, United Kingdom., Murray J; The Royal Marsden NHS Foundation Trust, London, United Kingdom; The Institute of Cancer Research, London, United Kingdom., Parker C; The Royal Marsden NHS Foundation Trust, London, United Kingdom; The Institute of Cancer Research, London, United Kingdom., Palaniappan N; Velindre Cancer Centre, Cardiff, United Kingdom., Pathmanathan A; The Royal Marsden NHS Foundation Trust, London, United Kingdom; The Institute of Cancer Research, London, United Kingdom., Reid A; The Royal Marsden NHS Foundation Trust, London, United Kingdom., Suh YE; The Royal Marsden NHS Foundation Trust, London, United Kingdom., Syndikus I; The Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, United Kingdom., Tirona A; The Royal Marsden NHS Foundation Trust, London, United Kingdom., Tran A; The Royal Marsden NHS Foundation Trust, London, United Kingdom., Tunariu N; The Royal Marsden NHS Foundation Trust, London, United Kingdom; The Institute of Cancer Research, London, United Kingdom., van As NJ; The Royal Marsden NHS Foundation Trust, London, United Kingdom; The Institute of Cancer Research, London, United Kingdom., Wylie J; The Christie NHS Foundation Trust, Manchester, United Kingdom., Tree AC; The Royal Marsden NHS Foundation Trust, London, United Kingdom; The Institute of Cancer Research, London, United Kingdom.
Source: International journal of radiation oncology, biology, physics [Int J Radiat Oncol Biol Phys] 2026 May 01; Vol. 125 (1), pp. 285-294. Date of Electronic Publication: 2025 Mar 09.
Publication Type: Journal Article; Clinical Trial, Phase II; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Elsevier, Inc Country of Publication: United States NLM ID: 7603616 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-355X (Electronic) Linking ISSN: 03603016 NLM ISO Abbreviation: Int J Radiat Oncol Biol Phys Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1879-355X
DOI:10.1016/j.ijrobp.2025.02.046